Lantern Pharma Inc. - FORM S-1 - EX-23.1 - CONSENT OF EISNERAMPER LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - April 16, 2020

Attached files

file filename
EX-10.10 - AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENT WITH ONCOLOGY VENTURE - Lantern Pharma Inc.ea120601fs1ex10-10_lantern.htm
S-1 - REGISTRATION STATEMENT - Lantern Pharma Inc.ea120601-s1_lanternpharma.htm
EX-21.1 - LIST OF SUBSIDIARY - Lantern Pharma Inc.ea120601fs1ex21-1_lantern.htm
EX-14.1 - CODE OF BUSINESS CONDUCT AND ETHICS - Lantern Pharma Inc.ea120601fs1ex14-1_lantern.htm
EX-10.12 - ADDENDUM TO TECHNOLOGYLICENSE AGREEMENT DATED FEBRUARY 8, 2016, WITH AF CHEMICAL - Lantern Pharma Inc.ea120601fs1ex10-12_lantern.htm
EX-10.11 - ASSIGNMENT AGREEMENTDATED AS OF JANUARY 5, 2018 WITH BIONUMERIK PHARMACEUTICALS, - Lantern Pharma Inc.ea120601fs1ex10-11_lantern.htm
EX-10.9 - ADDENDUM TO DRUG LICENSE AND DEVELOPMENT AGREEMENT WITH ONCOLOGY VENTURE A/S DAT - Lantern Pharma Inc.ea120601fs1ex10-9_lantern.htm
EX-10.8 - DRUG LICENSE AND DEVELOPMENT AGREEMENT DATED AS OF MAY 23, 2015 WITH ONCOLOGY VE - Lantern Pharma Inc.ea120601fs1ex10-8_lantern.htm
EX-10.7 - TECHNOLOGY LICENSE AGREEMENT DATED JANUARY 15,2015, WITH AF CHEMICALS LLC - Lantern Pharma Inc.ea120601fs1ex10-7_lantern.htm
EX-10.6 - AMENDED AND RESTATED VOTING AGREEMENT - Lantern Pharma Inc.ea120601fs1ex10-6_lantern.htm
EX-10.5 - AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT - Lantern Pharma Inc.ea120601fs1ex10-5_lantern.htm
EX-10.4 - AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT - Lantern Pharma Inc.ea120601fs1ex10-4_lantern.htm
EX-10.3 - FORM OF INDEMNIFICATION AGREEMENT - Lantern Pharma Inc.ea120601fs1ex10-3_lantern.htm
EX-10.2 - EMPLOYMENT AGREEMENT DATED JULY 23, 2018 WITH PANNA SHARMA - Lantern Pharma Inc.ea120601fs1ex10-2_lantern.htm
EX-10.1 - AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN - Lantern Pharma Inc.ea120601fs1ex10-1_lantern.htm
EX-4.1(III) - FORM OF WARRANT (2019) - Lantern Pharma Inc.ea120601fs1ex4-1iii_lantern.htm
EX-4.1(II) - FORM OF WARRANT (2017) - Lantern Pharma Inc.ea120601fs1ex4-1ii_lantern.htm
EX-4.1(I) - FORM OF WARRANT (2014) - Lantern Pharma Inc.ea120601fs1ex4-1i_lantern.htm
EX-3.1(IV) - BYLAWS - Lantern Pharma Inc.ea120601fs1ex3-1iv_lantern.htm
EX-3.1(III) - CERTIFICATE OF INCORPORATION - Lantern Pharma Inc.ea120601fs1ex3-1iii_lantern.htm
EX-3.1(II) - CERTIFICATE OF CONVERSION (DELAWARE) - Lantern Pharma Inc.ea120601fs1ex3-1ii_lantern.htm
EX-3.1(I) - CERTIFICATE OF CONVERSION (TEXAS) - Lantern Pharma Inc.ea120601fs1ex3-1i_lantern.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the inclusion in this Registration Statement of Lantern Pharma Inc. and Subsidiary on Form S-1 (No. XXX-XXXXX) to be filed on or about April 16, 2020 of our report dated April 16, 2020, on our audits of the consolidated financial statements as of December 31, 2019 and 2018 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.

 

/s/ EisnerAmper LLP

 

EISNERAMPER LLP

Iselin, New Jersey

April 16, 2020

 

Lantern Pharma Inc. Reports